Podcast #1 - The Adaptive Launch
- Jonathan Olsen
- 2 days ago
- 2 min read
Your best launch plan has a shelf life of about three months.
That is how long a single tactic has traditionally taken to turn around, inside a window that runs six months to a year.
Lou Pillai on what changes when a launch runs as a closed loop rather than a static map.
The stakes show up at patient access, where a two-week wait starts costing you prescribers.
That three months is the honest number: rework the content, re-run the review, get it back into the field. Teams can spend half their window reacting to a signal they first saw on day one.
On the first episode of our podcast, biopharma CIO/CDO @Lou Pillai described the difference between a map and a living system.
The traditional launch is a map. Drawn from best practices, populated with solution patterns, locked before go-live. The trouble with maps is that they do not update themselves. The adaptive version connects data, teams, and capabilities so that when the market streams signals back, a segment that is not converting, a model that is not landing in a region, the loop closes in days rather than quarters. Compliantly.
Where this gets concrete is patient access. The first patient on a new therapy often waits the longest. When that wait stretches past two weeks, prescribers start to disengage, and you hear the line every launch team dreads: I cannot seem to get my patients on this drug. In a competitive category, that is the difference between a launch that accelerates in the first six months and one that never recovers the curve.
Adaptive launch is not about replacing the plan. It is about shrinking the distance between a signal and a response.
Listen to this part of the conversation here: https://vimeo.com/1210362697?share=copy&fl=sv&fe=ci.
Comments